BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37906288)

  • 1. Breast cancer immunopeptidomes contain numerous shared tumor antigens.
    Kina E; Laverdure JP; Durette C; Lanoix J; Courcelles M; Zhao Q; Apavaloaei A; Larouche JD; Hardy MP; Vincent K; Gendron P; Hesnard L; Thériault C; Ruiz Cuevas MV; Ehx G; Thibault P; Perreault C
    J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37906288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens.
    Hesnard L; Thériault C; Cahuzac M; Durette C; Vincent K; Hardy MP; Lanoix J; Lavallée GO; Humeau J; Thibault P; Perreault C
    Curr Oncol; 2024 May; 31(6):3099-3121. PubMed ID: 38920720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.
    Zhao Q; Laverdure JP; Lanoix J; Durette C; Côté C; Bonneil É; Laumont CM; Gendron P; Vincent K; Courcelles M; Lemieux S; Millar DG; Ohashi PS; Thibault P; Perreault C
    Cancer Immunol Res; 2020 Apr; 8(4):544-555. PubMed ID: 32047025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.
    Ehx G; Larouche JD; Durette C; Laverdure JP; Hesnard L; Vincent K; Hardy MP; Thériault C; Rulleau C; Lanoix J; Bonneil E; Feghaly A; Apavaloaei A; Noronha N; Laumont CM; Delisle JS; Vago L; Hébert J; Sauvageau G; Lemieux S; Thibault P; Perreault C
    Immunity; 2021 Apr; 54(4):737-752.e10. PubMed ID: 33740418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCGA RNA-Seq and Tumor-Infiltrating Lymphocyte Imaging Data Reveal Cold Tumor Signatures of Invasive Ductal Carcinomas and Estrogen Receptor-Positive Human Breast Tumors.
    Bou-Dargham MJ; Sha L; Sarker DB; Krakora-Compagno MZ; Chen Z; Zhang J; Sang QA
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
    O'Melia MJ; Manspeaker MP; Thomas SN
    Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
    Wu Y; Yi Z; Li J; Wei Y; Feng R; Liu J; Huang J; Chen Y; Wang X; Sun J; Yin X; Li Y; Wan J; Zhang L; Huang J; Du H; Wang X; Li Q; Ren G; Li H
    Theranostics; 2022; 12(10):4564-4580. PubMed ID: 35832090
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities for Antigen Discovery in Metastatic Breast Cancer.
    Sood AK; Nemeth M; Wang J; Wu Y; Gandhi S
    Front Immunol; 2020; 11():570049. PubMed ID: 33193348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.